Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,396 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Genentech, Inc. Clear all
Terminated Phase 2 Interventional Results available

Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease

NCT02337517
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Laboratory Biomarker Analysis, Vismodegib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Ann Arbor, Michigan • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 23, 2026, 8:36 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events

NCT07448038
View directory record Official record
Conditions
Atherosclerosis
Interventions
Selnoflast, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
24
States / cities
Beverly Hills, California • Irvine, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 23, 2026, 8:36 AM EDT
Terminated Phase 2 Interventional Results available

Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer

NCT00461773
View directory record Official record
Conditions
Hormone-Sensitive Breast Cancer, Breast Cancer
Interventions
Letrozole, Bevacizumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Oct 23, 2026, 8:36 AM EDT
Completed Phase 1 Interventional

A Study to Assess Safety and Pharmacokinetics of MOXR0916 in Participants With Locally Advanced or Metastatic Solid Tumors

NCT02219724
View directory record Official record
Conditions
Neoplasms
Interventions
MOXR0916
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
12
States / cities
Scottsdale, Arizona • Aurora, Colorado • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 23, 2026, 8:36 AM EDT
Completed Phase 1 Interventional

A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma

NCT01547546
View directory record Official record
Conditions
Glioblastoma, Glioma
Interventions
GDC-0084
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 23, 2026, 8:36 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy

NCT02993523
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Azacitidine, Venetoclax, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
24
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 23, 2026, 8:36 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

NCT04449874
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors
Interventions
GDC-6036, Atezolizumab, Cetuximab, Bevacizumab, Erlotinib, GDC-1971, Inavolisib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
9
States / cities
Duarte, California • La Jolla, California • Orange, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 23, 2026, 8:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers

NCT01711762
View directory record Official record
Conditions
Healthy Volunteer
Interventions
GDC-0973
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 23, 2026, 8:36 AM EDT
Completed Phase 1 Interventional

Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas

NCT02639117
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
Vismodegib
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 23, 2026, 8:36 AM EDT
Completed Phase 1 Interventional

A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)

NCT02966782
View directory record Official record
Conditions
Myelodysplastic Syndromes (MDS)
Interventions
venetoclax, azacitidine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
10
States / cities
Tucson, Arizona • Aurora, Colorado • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 23, 2026, 8:36 AM EDT
Completed Phase 1 Interventional

Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer

NCT00543842
View directory record Official record
Conditions
Rectal Cancer
Interventions
Bevacizumab, Capecitabine, Erlotinib, Radiation Therapy, Surgery
Drug · Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2015 · Synced Oct 23, 2026, 8:36 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma

NCT00795665
View directory record Official record
Conditions
Glioma
Interventions
bevacizumab, carmustine
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 23, 2026, 8:36 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT01366209
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Pirfenidone, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 23, 2026, 8:36 AM EDT
Terminated Phase 4 Interventional Results available

A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal

NCT02317276
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Triamcinolone 0.1%
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Oct 23, 2026, 8:36 AM EDT
Completed Phase 1 Interventional

A Phase I Trial of Capecitabine in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer

NCT00480584
View directory record Official record
Conditions
Metastatic Pancreatic Carcinoma
Interventions
gemcitabine, capecitabine, erlotinib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 8, 2012 · Synced Oct 23, 2026, 8:36 AM EDT
Completed Phase 2 Interventional Results available

Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas

NCT01088815
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Gemcitabine, nab-Paclitaxel, GDC-0449
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
3
States / cities
Scottsdale, Arizona • Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 23, 2026, 8:36 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Faricimab in Patients With NPDR

NCT05681884
View directory record Official record
Conditions
Non-Proliferative Diabetic Retinopathy
Interventions
Faricimab
Drug
Lead sponsor
Greater Houston Retina Research
Other
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
16
States / cities
Bakersfield, California • Modesto, California • Orlando, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 23, 2026, 8:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Biodistribution and Safety of [18F]GTP1 in Healthy Japanese Participants

NCT04394845
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[18F]GTP1
Diagnostic Test
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 23, 2026, 8:36 AM EDT
Terminated Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE)

NCT06602453
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
GDC-8264, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
40 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Stanford, California • Tampa, Florida • Lutherville, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 23, 2026, 8:36 AM EDT
Completed Phase 2 Interventional Results available

FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL)

NCT00448019
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Fludarabine, Cyclophosphamide, Rituximab, Bevacizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Oct 23, 2026, 8:36 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma

NCT01266031
View directory record Official record
Conditions
Malignant Glioma, Recurrent Glioblastoma
Interventions
vorinostat, bevacizumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 23, 2026, 8:36 AM EDT
Terminated Phase 2 Interventional Results available

A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy

NCT03029832
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
MOXR0916, Atezolizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
15
States / cities
Tucson, Arizona • Denver, Colorado • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated May 31, 2019 · Synced Oct 23, 2026, 8:36 AM EDT
Active, not recruiting Phase 2 Interventional

Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC

NCT05798663
View directory record Official record
Conditions
NSCLC
Interventions
Atezolizumab, Tiragolumab
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
15
States / cities
La Jolla, California • Oakland, California • Roseville, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 8:36 AM EDT
Completed Phase 1 Interventional

A Study of GDC-0941 in Participants With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable

NCT00876109
View directory record Official record
Conditions
Solid Cancers
Interventions
GDC-0941
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
3
States / cities
Scottsdale, Arizona • Boston, Massachusetts • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 23, 2026, 8:36 AM EDT